PMID- 16848645
OWN - NLM
STAT- MEDLINE
DCOM- 20070827
LR  - 20190902
IS  - 1555-2101 (Electronic)
IS  - 0160-6689 (Linking)
VI  - 67
IP  - 6
DP  - 2006 Jun
TI  - Extended-release bupropion for patients with major depressive disorder presenting 
      with symptoms of reduced energy, pleasure, and interest: findings from a 
      randomized, double-blind, placebo-controlled study.
PG  - 865-73
AB  - OBJECTIVE: This multicenter, double-blind, placebo-controlled study evaluated the 
      efficacy and safety of extended-release bupropion (bupropion XL) in the treatment 
      of major depressive disorder (MDD) with prominent symptoms of decreased energy, 
      pleasure, and interest. METHOD: Eligible adult outpatients meeting DSM-IV 
      criteria for MDD were randomly assigned to bupropion XL 300 to 450 mg/day (N = 
      135) or placebo (N = 139) for 8 weeks. The primary efficacy measure, change from 
      baseline on the 30-item Inventory of Depressive Symptomatology-Self Report 
      (IDS-IVR-30) total score, was obtained using interactive voice response (IVR) 
      technology. Secondary measures included change from baseline on the 30-item 
      Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C-30) total score and 
      change in domain subset scores for energy, pleasure, and interest; for insomnia; 
      and for anxiety. Response and remission rates were also calculated. Safety was 
      assessed by withdrawal rates, adverse events (AEs), body weight, and vital signs. 
      The study was conducted from June 24, 2003, to June 30, 2004. RESULTS: Bupropion 
      XL was superior to placebo at endpoint in reducing the IDS-IVR-30 total score (p 
      = .018) and the energy, pleasure, and interest domain (p = .007) and the insomnia 
      domain (p = .023) scores. IDS-C-30 outcomes were also significant (p < .001; p < 
      .001, and p = .008, respectively). Clinician-rated remission rates were 
      significantly higher with bupropion XL than placebo (32% vs. 18%, IDS-C-30; 41% 
      vs. 27%, IDS-IVR-30), as were response rates (50% vs. 35%, IDS-C-30; 53% vs. 38%, 
      Clinical Global Impressions-Improvement of Illness). Most AEs were mild or 
      moderate. The incidence of a >or= 7% body weight loss was 3.7% with bupropion XL 
      and 1.4% with placebo. CONCLUSION: Bupropion XL was effective and well tolerated 
      in MDD patients with decreased energy, pleasure, and interest.
FAU - Jefferson, James W
AU  - Jefferson JW
AD  - Madison Institute of Medicine, Madison, WI 53717, USA. 
      jjefferson@healthtechsys.com
FAU - Rush, A John
AU  - Rush AJ
FAU - Nelson, J Craig
AU  - Nelson JC
FAU - VanMeter, Susan A
AU  - VanMeter SA
FAU - Krishen, Alok
AU  - Krishen A
FAU - Hampton, Kenneth D
AU  - Hampton KD
FAU - Wightman, Donna S
AU  - Wightman DS
FAU - Modell, Jack G
AU  - Modell JG
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Clin Psychiatry
JT  - The Journal of clinical psychiatry
JID - 7801243
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 01ZG3TPX31 (Bupropion)
RN  - BH3B64OKL9 (4-Aminopyridine)
SB  - IM
MH  - 4-Aminopyridine
MH  - Adult
MH  - Aged
MH  - Antidepressive Agents, Second-Generation/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Anxiety/drug therapy/etiology
MH  - Bupropion/administration & dosage/adverse effects/*therapeutic use
MH  - Depressive Disorder, Major/complications/*drug therapy
MH  - Double-Blind Method
MH  - Fatigue/drug therapy/etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Sleep Initiation and Maintenance Disorders/drug therapy/etiology
MH  - Treatment Outcome
EDAT- 2006/07/20 09:00
MHDA- 2007/08/28 09:00
CRDT- 2006/07/20 09:00
PHST- 2006/07/20 09:00 [pubmed]
PHST- 2007/08/28 09:00 [medline]
PHST- 2006/07/20 09:00 [entrez]
AID - 10.4088/jcp.v67n0602 [doi]
PST - ppublish
SO  - J Clin Psychiatry. 2006 Jun;67(6):865-73. doi: 10.4088/jcp.v67n0602.